Underwriters’ over-allotment is an additional 1,278,000 shares.
Net proceeds will be used for commercialization of FINTEPLA and MT1621, funding of future clinical trials, for working capital and general corporate purposes.
Closing date is March 6.
Shares are down 4% premarket.
Previously: Zogenix -2.5% amid proposed stock offering (March 3)